Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention.
Prospective studies of prediabetic subjects have shown that obesity and its duration are major risk factors for type 2 diabetes. Longitudinal studies are consistent with an etiologic role of subclinical inflammation in the pathogenesis of type 2 diabetes, primarily as a mediator of obesity-induced insulin resistance. Inflammation is closely associated with endothelial dysfunction and is recognized as one of the cardiovascular risk factors clustering in the Insulin Resistance Syndrome or Metabolic Syndrome. The adipose tissue has been recognized as an important source of metabolically active secretory products (adipocytokines), free fatty acids, leptin, TNF-alpha, Iinterleucin-6, plasminogen activator inhibitor-1, adiponectin and resistin. Prevention of insulin resistance by weight loss, diet and exercise is very effective in reducing the progression from glucose intolerance to type 2 diabetes in obese subjects. Since insulin resistance is a key disturbance in early type 2 diabetes additional drug treatment with insulin-sensitizing drugs might be helpful to reduce the progression to both beta-cell failure and macrovascular late complications. The PROACTIVE study will determine if the effects of improving insulin sensitivity and reducing inflammation will translate into clinical benefits and reduce the cardiovascular morbidity and mortality associated with insulin resistance and Type 2 diabetes.
Schernthaner
Gerit-Holger
GH
Department of Internal Medicine II, Division of Angiology, Medical University Vienna, Austria.
Schernthaner
Guntram
G
D052242:Adiponectin; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D007249:Inflammation / Q000150:complications*; D007333:Insulin Resistance; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood; D024821:Metabolic Syndrome / Q000150:complications; D009765:Obesity / Q000150:complications; D047493:PPAR alpha / Q000502:physiology; D045162:Thiazolidinediones / Q000627:therapeutic use
D052242:Adiponectin; D036341:Intercellular Signaling Peptides and Proteins; D047493:PPAR alpha; D045162:Thiazolidinediones